FDA Grants Fast Track Designation to Cardium's Phase 3 Angiogenic Gene Therapy for Heart Disease (PRWeb)
Cardium Therapeutics (OTCBB:CDTP) announced that the U.S. Food and Drug Administration (FDA) has granted fast track designation to the Company's lead product candidate, Generx(TM) (alferminogene tadenovec, Ad5FGF-4) for the potential treatment of myocardial ischemia. Myocardial ischemia, insufficient blood flow within the heart muscle, gives rise to angina associated with coronary heart disease. ...

MIGENIX Reports Fourth Quarter and Fiscal Year 2007 Financial Results (CNW Group via Yahoo! Finance)
MIGENIX Inc. , a clinical-stage developer of drugs for infectious diseases, reports financial results for the three months and year ended April 30, 2007 and an update on its programs.

Novartis Sees Slowdown, $4 Billion Share Buyback (Update1) (Bloomberg.com)
July 17 (Bloomberg) -- Novartis AG, Europe's third-largest drugmaker, forecast slowing sales growth because of generic competition and delayed regulatory approvals, and said it will buy back $4 billion of stock.